BCG-unresponsive
The FDA's definition of early bladder cancer that has failed adequate BCG treatment, the population in which most new bladder drugs are first approved.
Persistent or recurrent CIS within 12 months of adequate BCG (at least 5 of 6 induction and 2 of 3 maintenance doses), or high-grade Ta/T1 recurrence within 6 months, or T1 high-grade at first evaluation after induction. Historically treated with radical cystectomy; now pembrolizumab, nadofaragene, N-803 + BCG, TAR-200, and (filing) cretostimogene offer bladder-sparing options with CR rates of 40-80%.
Pages like this
not linked directly; found by shared links- IdeaTrain the bone marrow to make better anti-tumour immune cells
Shares Intravesical BCG, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
- TermNon-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)
Shares Intravesical BCG, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
- IdeaOncolytic viruses that make interleukin-12 only inside the tumour
Shares Nadofaragene firadenovec, Cretostimogene grenadenorepvec, Bladder & urothelial cancer.
- CompanyFerring Pharmaceuticals
Shares Nadofaragene firadenovec, Bladder & urothelial cancer.
- CompanyCG Oncology
Shares Cretostimogene grenadenorepvec, Bladder & urothelial cancer.
- CompanyImmunityBio
Shares Nogapendekin alfa inbakicept, Bladder & urothelial cancer.
- IdeaEngineered bacteria that live in tumours and manufacture drugs there
Shares Intravesical BCG, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy).
- PairingDurvalumab + BCG in BCG-naive high-risk NMIBC